NAT screening of blood and plasma donations: evolution of technology and regulatory policy*

Authors


  • ABBREVIATIONS:

    BLA = Biologics License Application; IND(s) = investigational new drug application(s).

  • *

    Presented in part at the annual meeting of the Society for Japanese Blood Programme, September 26, 2001. Portions were published in the proceedings of that meeting in Blood Programme (Ketsueki Jigyou) 2002;24:550-4, the journal of the Society for Japanese Blood Programme.

Address reprint requests to: Edward Tabor, MD, Office of Blood Research and Review, HFM-300, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-1448; e-mail: tabor@cber.fda.gov .

Ancillary